Table 8 Outcomes of multivariate analyses in the PP population (n = 141) between the MPR group and the non-MPR group.

From: Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB–IIIB lung squamous cell carcinoma

Characteristic

P-value

OR

95%CI

Clinical stage

 IB

0.999

0.000

–

 IIA

0.999

0.000

–

 IIB

–

1

–

 IIIA

0.083

2.717

0.878–8.409

 IIIB

0.939

1.046

0.328–3.333

Therapeutic evaluation

 SD

–

1

–

 CR/PR

0.515

1.324

0.568–3.085

Therapeutic regimen

 Chemotherapy

–

1

–

 Immunochemotherapy

 < 0.001

7.406

3.054–17.960

  1. PP, postoperative; OR, odds ratio; CR, complete remission; PR, partial remission; SD, stable disease.
  2. Significant values are in bold.
Back to article page